Free Trial Information
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
Read More
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

...inhibiting CCNE2 could help treat liver cancer. Dana-Farber Cancer Institute Distillery Therapeutics Lymphoma; neuroendocrine tumors Solute carrier family 43 member 1...
Read More
BioCentury | Jan 17, 2018
Distillery Therapeutics

Cancer

...in preclinical testing to treat glioblastoma. TARGET/MARKER/PATHWAY: Solute carrier family 7 member 5 (SLC7A5; LAT1); solute carrier family 43 member 1...
...University of Science and Technology, Wuhan, China email: qingguoliang@whu.edu.cn Hongjiang Li Huazhong University of Science and Technology Wuhan University Solute carrier family 43 member 1...
Read More
Items per page:
1 - 3 of 3